Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: Retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase

Journal of Virology

Volumn 71, Issue 4, 1997, Pages 3023-3030

  Borkow, Gadi ^a   Barnard, John ^a   Nguyen, Thuy Minh ^a   Belmonte, Antoinetta ^a   Wainberg, Mark A ^a   Parniak, Michael A ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DNA POLYMERASE; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NEVIRAPINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL ISOLATION; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; REVERSE TRANSCRIPTION; VIROGENESIS; VIRUS INACTIVATION; VIRUS INFECTION; VIRUS REPLICATION;

EID: 0030997133     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.71.4.3023-3030.1997     Document Type: Article

References (30)

1. Baba, M., R. Pauwels, J. Balzarini, J. Arnout, J. Desmyter, and E. De Clercq. 1988. Mechanism of the inhibitory effect of dextran sulfate and heparin on the replication of human immunodeficiency virus in vitro. Proc. Natl. Acad. Sci. USA 85:6132-6136.
2. Bader, J. P., J. B. McMahon, R. J. Schultz, V. L. Narayanan, J. B. Pierce, O. S. Weislow, C. F. Midelfort, S. F. Stinson, and M. R. Boyd. 1991. Oxathiin carboxanilide, a potent inhibitor of human immunodeficiency virus reproduction. Proc. Natl. Acad. Sci. USA 88:6740-6744.
3. Balzarini, J., W. G. Brouwer, D. C. Dao, E. M. Osika, and E. Declercq. 1996. Identification of novel thiocarboxanilide derivatives that suppress a variety of drug-resistant mutant human immunodeficiency virus type 1 strains at a potency similar to that for wild-type virus. Antimicrob. Agents Chemother. 40:1454-1466.
4. Barnard, J., G. Borkow, and M. A. Parniak. Submitted for publication.
5. Borkow, G., N. Kaushik, and M. A. Parniak. Unpublished data.
6. Connolly, K. J., and S. M. Hammer. 1992. Antiretroviral therapy: reverse transcriptase inhibition. Antimicrob. Agents Chemother. 36:245-254.
7. Fletcher, R. S., K. Syed, S. Mithani, G. I. Dmitrienko, and M. A. Parniak. 1995. Carboxanilide derivative nonnucleoside inhibitors of HIV-1 reverse transcriptase interact with different mechanistic forms of the enzyme. Biochemistry 34:4036-4042.
8. Fletcher, R. S., D. Arion, G. Borkow, M. A. Wainberg, G. I. Dmitrienko, and M. A. Parniak. 1995. Synergistic inhibition of HIV-1 reverse transcriptase DNA polymerase activity and virus replication in vitro by combinations of carboxanilide nonnucleoside compounds. Biochemistry 34:10106-10112.
9. Fletcher, R. S., G. Holleschak, E. Nagy, D. Arion, G. Borkow, Z. Gu, M. A. Wainberg, G. I. Dmitrienko, and M. A. Parniak. 1996. Single step purification of HIV-1 recombinant wild type and mutant reverse transcriptase. Protein Expr. Purif. 7:27-32.
10. Grob, P. M., J. C. Wu, K. A. Cohen, R. H. Ingraham, C.-K. Shih, K. D. Hargrave, T. L. Mctague, and V. J. Merluzzi. 1992. Nonnucleoside inhibitors of HIV-1 reverse transcriptase: nevirapine as a prototype drug. AIDS Res. Hum. Retroviruses 8:145-152.
11. Hirabayashi, K., S. Iwata, M. Ito, S. Shigeta, T. Narui, T. Mori, and S. Shibata. 1989. Inhibiting effect of a lichen polysaccharide sulfate, GE-3-S, on the replication of human immunodeficiency virus (HIV) in vitro. Chem. Pharm. Bull. 37:2410-2412.
12. Johnson, V. A. 1996. Combination therapy for HIV-1 infection. Overview: preclinical and clinical analysis of antiretroviral combinations. Antivir. Res. 29:35-39.
13. Levy, J. A. 1993. Pathogenesis of human immunodeficiency virus infection. Microbiol. Rev. 57:183-289.
14. McMahon, J. B., Jr., R. W. Buckheit, J. R. Gulakowski, M. J. Currens, D. T. Vistica, R. H. Shoemaker, S. F. Stinson, J. D. Russell, J. P. Bader, V. L. Narayanan, R. J. Schultz, W. G. Brouwer, E. E. Felauer, and M. R. Boyd. 1996. Biological and biochemical anti-human immunodeficiency virus activity of UC38, a new nonnucleoside reverse transcriptase inhibitor. J. Pharmacol. Exp. Ther. 276:298-305.
15. Merluzzi, V. J., K. D. Hargrave, M. Labadia, K. Grozinger, M. T. Skoog, J. C. Wu, C.-K. Shih, K. Eckner, S. Hattox, J. Adams, A. S. Rosehthal, R. Faanes, R. J. Eckner, R. A. Koup, and J. L. Sullivan. 1990. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 250:1411-1413.
16. Merson, M. H. 1993. Slowing the spread of HIV: agenda for the 1990s. Science 260:1266-1268.
17. Mitsuya, H., D. J. Looney, S. Kuno, R. Ueno, F. Wong-Staal, and S. Broder. 1988. Dextran sulfate suppression of viruses in the HIV family: inhibition of virion binding to CD4+ cells. Science 240:646-649.
18. Moyle, G., and B. Gazzard. 1996. Current knowledge and future prospects for the use of HIV protease inhibitors. Drugs 51:701-712.
19. Neurath, A. R., S. B. Jiang, N. Strick, K. Lin, Y. Y. Li, and A. K. Debnath. 1996. Bovine β-lactoglobulin modified by 3-hydroxyphthalic anhydride blocks the CD4 cell receptor for HIV. Nat. Med. 2:230-234.
20. Niruthisard, S., R. E. Roddy, and S. Chutivongse. 1991. The effects of frequent nonoxynol-9 use on the vaginal and cervical mucosa. Sex. Transm. Dis. 18:176-179.
21. Pauwels, R., and E. De Clercq. 1996. Development of vaginal microbicides for the prevention of heterosexual transmission of HIV. J. Acquired Immun. Defic. Syndromes Hum. Retrovirol. 11:211-221.
22. Potts, M. 1994. The urgent need for a vaginal microbicide in the prevention of HIV transmission. Am. J. Public Health 84:890-891.
23. Roddy, R. E., M. Cordero, and J. A. Fortney. 1993. A dosing study of nonoxynol-9 and genital irritation. Int. J. STD AIDS 4:165-170.
24. Rooke, R., M. Tremblay, and M. A. Wainberg. 1990. AZT (zidovudine) may act post-integrationally to inhibit generation of HIV-1 progeny virus in chronically-infected cells. Virology 176:205-215.
25. Rooke, R., M. A. Parniak, M. Tremblay, H. Soudeyns, X. Li, Q. Gao, X.-J. Yao, and M. A. Wainberg. 1991. Biological comparison of wild-type and zidovudine-resistant isolates of human immunodeficiency virus type 1 from the same subjects: susceptibility and resistance to other drugs. Antimicrob. Agents Chemother. 35:988-991.
26. Szedlacsek, S. E., and R. G. Duggleby. 1995. Kinetics of slow and tight-binding inhibitors. Methods Enzymol. 249:144-180.
27. Williams, J. W., and J. F. Morrison. 1979. The kinetics of reversible tight-binding inhibition. Methods Enzymol. 63:437-467.
28. Yao, X.-J., M. A. Wainberg, and M. A. Parniak. 1992. Mechanism of inhibition of HIV-1 infection in vitro by purified extract of Prunella vulgaris. Virology 187:56-62.
29. Zhang, H., G. Dornadula, and R. J. Pomerantz. 1996. Endogenous reverse transcription of human immunodeficiency virus type 1 in physiological microenvironments: an important stage for viral infection of nondividing cells. J. Virol. 70:2809-2824.
30. Zhang, H., Y. Zhang, T. P. Spicer, L. Z. Abbott, M. Abbott, and B. J. Poiesz. 1993. Reverse transcription takes place within extracellular HIV-1 virions: potential biological significance. AIDS Res. Hum. Retroviruses 9:1287-1296.